XML 49 R39.htm IDEA: XBRL DOCUMENT v3.20.2
Share-based Compensation (Tables)
3 Months Ended
Sep. 30, 2020
Share-based Compensation  
Schedule of weighted average assumptions

September 30, 2020

September 30, 2019

Risk-free interest rate

0.2

%

1.9

%

Expected volatility

82.5

%

73.7

%

Expected dividend yield

%

%

Forfeiture rate

%

%

Expected term

5.0

years

5.1

years

Weighted average fair value

$

3.86

$

4.04

Summary of stock option award activity

    

    

    

    

    

Weighted

Weighted-

Average

Average

Aggregate

Remaining

Exercise

Intrinsic

Contractual

(In thousands, except for weighted average price and life data)

    

Awards

    

Price

    

Value

    

Life (yrs.)

Outstanding at June 30, 2020

 

991

12.11

$

678

5.6

Granted

 

309

5.95

Exercised

 

(32)

4.16

$

48

Forfeited, expired or repurchased

 

(187)

16.56

Outstanding at September 30, 2020

 

1,081

9.81

$

186

 

7.8

Vested and expected to vest at September 30, 2020

 

408

14.92

$

136

 

5.3

Exercisable at September 30, 2020

 

1,079

9.81

$

186

 

7.8

Summary of non-vested restricted stock awards

Weighted

Average Grant -

Aggregate

(In thousands, except for weighted average price data)

    

Awards

    

date Fair Value

    

Intrinsic Value

Non-vested at June 30, 2020

 

1,344

$

8.70

Granted

 

870

 

5.72

Vested

 

(664)

 

8.75

$

3,798

Forfeited

 

(66)

 

9.32

Non-vested at September 30, 2020

 

1,484

$

6.90

Schedule of non-vested performance-based shares

Weighted

Average Grant -

(In thousands, except for weighted average price and life data)

    

Awards

    

date Fair Value

    

Non-vested at June 30, 2020

 

204

$

12.99

Granted

 

339

$

9.22

Performance adjustment (1)

(12)

$

25.58

Non-vested at September 30, 2020

 

531

$

10.29

(1)Represents the adjustment based on the performance of the September 2017 awards, which was below the Threshold goal level at the end of the three-year performance period
Schedule of allocation of share-based compensation

Three Months Ended

September 30, 

(In thousands)

    

2020

    

2019

Selling, general and administrative expenses

$

2,714

$

3,635

Research and development expenses

 

155

 

224

Cost of sales

 

473

 

600

Total

$

3,342

$

4,459

Tax benefit at statutory rate

$

752

$

1,003